Technical Analysis for SNDX - Syndax Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 14.19 -4.51% -0.67
SNDX closed down 4.51 percent on Thursday, April 22, 2021, on 1.92 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: May 5
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical SNDX trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish -4.51%
Older End-of-Day Signals for SNDX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 13 hours ago
Possible Inside Day about 13 hours ago
Down 5% about 17 hours ago
2x Volume Pace about 17 hours ago
1.5x Volume Pace about 17 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Breast Cancer Treatment Of Breast Cancer Antineoplastic Drugs Cancer Cell Cancer Therapies Lung Cancer Hematological Malignancies Pyridines Late Stage Biopharmaceutical National Cancer Institute Benzamides Carbamates Histone Deacetylase Inhibitor

Is SNDX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 27.85
52 Week Low 11.27
Average Volume 953,639
200-Day Moving Average 19.65
50-Day Moving Average 22.30
20-Day Moving Average 21.01
10-Day Moving Average 18.90
Average True Range 1.86
ADX 20.94
+DI 10.40
-DI 37.34
Chandelier Exit (Long, 3 ATRs ) 20.11
Chandelier Exit (Short, 3 ATRs ) 18.59
Upper Bollinger Band 27.44
Lower Bollinger Band 14.59
Percent B (%b) -0.03
BandWidth 61.12
MACD Line -1.94
MACD Signal Line -1.00
MACD Histogram -0.9399
Fundamentals Value
Market Cap 579.93 Million
Num Shares 40.9 Million
EPS -2.36
Price-to-Earnings (P/E) Ratio -6.02
Price-to-Sales 565.36
Price-to-Book 7.05
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.42
Resistance 3 (R3) 15.48 15.12 15.22
Resistance 2 (R2) 15.12 14.81 15.10 15.15
Resistance 1 (R1) 14.66 14.62 14.48 14.60 15.08
Pivot Point 14.30 14.30 14.22 14.28 14.30
Support 1 (S1) 13.84 13.99 13.66 13.78 13.30
Support 2 (S2) 13.48 13.80 13.46 13.23
Support 3 (S3) 13.02 13.48 13.17
Support 4 (S4) 12.96